Look to Exact Sciences, Not Radient Pharma, for Best Colon Cancer Screen Test
Newly released performance data reveals that the Onko-Sure blood test, when combined with an older blood test, successfully detected the presence of early (stage 1) colon cancer in 48% of positive samples tested.
"Highly promising" is how Radient described the new Onko-Sure data in a statement released Monday. Patients and doctors interested in catching colon cancer early so that it can be more easily treated and cured will surely disagree.
The most desirable time to detect cancer in the colon is before fast-growing cells become malignant. Exact Sciences (EXAS) is developing a test that detects genetic abnormalities in stool samples. In preliminary studies to date, Exact's Cologuard has been able to successfully detect pre-cancerous lesions in 59% of samples tested. The same Cologuard test has been able to detect 100% of stage 1 colon cancer and 96% for colon cancer in stages I-III combined.Those are data that I'd rightfully call "highly promising." By comparison, the combination of Radient's Onko-Sure plus the older blood test managed a sensitivity, or positive detection rate, of just 58% for all four stages of colon cancer. The tests also had a 40% false positive rate, which means they detected the presence of colon cancer in samples where no cancer actually existed. The new Onko-Sure screening data were made public at last week's American Society of Clinical Oncology's Gastrointestinal Cancers Symposium. The results come from the so-called "Mayo Clinic" study, which Radient conducted after buying colon cancer samples from a subsidiary of the Mayo Clinic. Last year, Radient tried to mislead investors into believing that it was working in partnership with Mayo on the Onko-Sure test. Radient past public statements about findings from the Onko-Sure colon-cancer screening study don't accurately describe the actual data released last week. Radient markets Onko-Sure today as a test used by doctors to detect when colon cancer recurs in patients after treatment. The commercial opportunity for cancer recurrence tests is small and Radient has done a very poor job of selling Onko-Sure, evidenced by the company's dearth of revenue and a balance sheet which makes Greece look like a European economic giant.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV